Oncological and Reproductive Outcomes in Patients With Advanced-Stage Ovarian Immature Teratoma: Experience From a Tertiary Center

Overview

Journal Front Oncol

Specialty Oncology

Date 2022 Jul 11

PMID 35814432

Authors

Dan Wang

Wei Cang

Shan Zhu

Congwei Jia

Dongyan Cao

Jiaxin Yang

Yang Xiang

Affiliations

Soon will be listed here.

Abstract

Objective: To evaluate the oncological and reproductive outcomes in patients with advanced-stage ovarian immature teratoma (IMT).

Methods: We retrospectively reviewed the medical records of patients with advanced-stage IMT who were treated with surgery between January 1985 and December 2020. Fertility-sparing surgery (FSS) was defined as preservation of the uterus and at least one adnexa. Oncological outcomes were compared between patients who underwent FSS and radical surgery. Patients who underwent FSS were also contacted to gather information about their menstrual history and reproductive outcomes.

Results: Forty-six patients fulfilled the inclusion criteria, of whom 38 underwent FSS and eight were treated with radical surgery. Fifteen patients suffered recurrence after a median follow-up time of 74.2 months (range: 4.1-434.1 months). The 5-year disease-free survival (DFS) and overall survival (OS) rates were 69.1% and 89.9%, respectively. Multivariate analysis identified suboptimal cytoreductive surgery as the only independent risk factor for recurrence. There was no significant difference in DFS or OS between patients with different surgical procedures. Ten of the 15 relapsed patients had optimal salvage surgery and all remained alive with no evidence disease. Among the 32 patients who underwent FSS, 29 resumed menstruation after surgery, and five of seven patients who designed pregnancy achieved a total of five successful pregnancies.

Conclusions: Ovarian IMT has a favorable prognosis, even when diagnosed at an advanced stage. FSS is feasible in patients with advanced-stage IMT who wish to preserve their fertility. Patients may benefit from optimal cytoreductive surgery during initial and salvage surgery.

Citing Articles

Oncofertility and Fertility Preservation for Women with Gynecological Malignancies: Where Do We Stand Today?.

Di Nisio V, Daponte N, Messini C, Anifandis G, Antonouli S Biomolecules. 2024; 14(8).

PMID: 39199331 PMC: 11353009. DOI: 10.3390/biom14080943.

Growing teratoma syndrome of the ovary: a case report and literature review.

Tao J, Shi Z, Li M, Li T Front Oncol. 2024; 14:1412206.

PMID: 39077470 PMC: 11284059. DOI: 10.3389/fonc.2024.1412206.

Immature ovarian teratoma in a 20-year-old woman: A case report.

Errami L, Douzi A, Lamzouri O, Taheri H, Saadi H, Mimouni A J Int Med Res. 2024; 52(2):3000605241232568.

PMID: 38410854 PMC: 10898317. DOI: 10.1177/03000605241232568.

Obstetric Results after Fertility-Sparing Management of Non-Epithelial Ovarian Cancer.

Piatek S, Szymusik I, Sobiczewski P, Michalski W, Kowalska M, Oltarzewski M Cancers (Basel). 2023; 15(16).

PMID: 37627198 PMC: 10453521. DOI: 10.3390/cancers15164170.

Immature Teratoma: Diagnosis and Management-A Review of the Literature.

Moraru L, Mitranovici M, Chiorean D, Coros M, Moraru R, Oala I Diagnostics (Basel). 2023; 13(9).

PMID: 37174909 PMC: 10177811. DOI: 10.3390/diagnostics13091516.

References

Lai C, Chang T, Hsueh S, Wu T, Chao A, Chou H . Outcome and prognostic factors in ovarian germ cell malignancies. Gynecol Oncol. 2005; 96(3):784-91. DOI: 10.1016/j.ygyno.2004.11.027. View

Faure-Conter C, Pashankar F . Immature Ovarian Teratoma: When to Give Adjuvant Therapy?. J Pediatr Hematol Oncol. 2017; 39(7):487-489. DOI: 10.1097/MPH.0000000000000950. View

Robboy S, Scully R . Ovarian teratoma with glial implants on the peritoneum. An analysis of 12 cases. Hum Pathol. 1970; 1(4):643-53. DOI: 10.1016/s0046-8177(70)80062-4. View

NORRIS H, Zirkin H, BENSON W . Immature (malignant) teratoma of the ovary: a clinical and pathologic study of 58 cases. Cancer. 1976; 37(5):2359-72. DOI: 10.1002/1097-0142(197605)37:5<2359::aid-cncr2820370528>3.0.co;2-q. View

Mikus M, Benco N, Matak L, Planinic P, Coric M, Lovric H . Fertility-sparing surgery for patients with malignant ovarian germ cell tumors: 10 years of clinical experience from a tertiary referral center. Arch Gynecol Obstet. 2020; 301(5):1227-1233. DOI: 10.1007/s00404-020-05522-5. View

Li J, Wu X . Current Strategy for the Treatment of Ovarian Germ Cell Tumors: Role of Extensive Surgery. Curr Treat Options Oncol. 2016; 17(8):44. DOI: 10.1007/s11864-016-0416-2. View

Hu T, Fang Y, Sun Q, Zhao H, Ma D, Zhu T . Clinical management of malignant ovarian germ cell tumors: A 26-year experience in a tertiary care institution. Surg Oncol. 2019; 31:8-13. DOI: 10.1016/j.suronc.2019.08.006. View

Uccello M, Boussios S, Samartzis E, Moschetta M . Systemic anti-cancer treatment in malignant ovarian germ cell tumours (MOGCTs): current management and promising approaches. Ann Transl Med. 2021; 8(24):1713. PMC: 7812190. DOI: 10.21037/atm.2020.04.15. View

Gershenson D . Management of ovarian germ cell tumors. J Clin Oncol. 2007; 25(20):2938-43. DOI: 10.1200/JCO.2007.10.8738. View

10.

Ray-Coquard I, Morice P, Lorusso D, Prat J, Oaknin A, Pautier P . Non-epithelial ovarian cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018; 29(Suppl 4):iv1-iv18. DOI: 10.1093/annonc/mdy001. View

11.

Karalok A, Comert G, Kilic C, Turkmen O, Kilic F, Basaran D . Cytoreductive surgery in advanced stage malignant ovarian germ cell tumors. J Gynecol Obstet Hum Reprod. 2019; 48(7):461-466. DOI: 10.1016/j.jogoh.2019.06.006. View

12.

Sonneveld D, Sleijfer D, Koops H, Keemers-Gels M, Molenaar W, Hoekstra H . Mature teratoma identified after postchemotherapy surgery in patients with disseminated nonseminomatous testicular germ cell tumors: a plea for an aggressive surgical approach. Cancer. 1998; 82(7):1343-51. DOI: 10.1002/(sici)1097-0142(19980401)82:7<1343::aid-cncr18>3.0.co;2-6. View

13.

Park J, Kim D, Suh D, Kim J, Kim Y, Kim Y . Analysis of outcomes and prognostic factors after fertility-sparing surgery in malignant ovarian germ cell tumors. Gynecol Oncol. 2017; 145(3):513-518. DOI: 10.1016/j.ygyno.2017.03.023. View

14.

Tamauchi S, Kajiyama H, Yoshihara M, Ikeda Y, Yoshikawa N, Nishino K . Reproductive outcomes of 105 malignant ovarian germ cell tumor survivors: a multicenter study. Am J Obstet Gynecol. 2018; 219(4):385.e1-385.e7. DOI: 10.1016/j.ajog.2018.07.021. View

15.

Lee C, Song M, Park S, Ki E, Lee S, Lee K . Residual tumor after the salvage surgery is the major risk factors for primary treatment failure in malignant ovarian germ cell tumors: a retrospective study of single institution. World J Surg Oncol. 2011; 9:123. PMC: 3214187. DOI: 10.1186/1477-7819-9-123. View

16.

Brown J, Friedlander M, Backes F, Harter P, OConnor D, de La Motte Rouge T . Gynecologic Cancer Intergroup (GCIG) consensus review for ovarian germ cell tumors. Int J Gynecol Cancer. 2014; 24(9 Suppl 3):S48-54. DOI: 10.1097/IGC.0000000000000223. View

17.

Low J, Perrin L, Crandon A, Hacker N . Conservative surgery to preserve ovarian function in patients with malignant ovarian germ cell tumors. A review of 74 cases. Cancer. 2000; 89(2):391-8. View

18.

Pectasides D, Pectasides E, Kassanos D . Germ cell tumors of the ovary. Cancer Treat Rev. 2008; 34(5):427-41. DOI: 10.1016/j.ctrv.2008.02.002. View

19.

Bentivegna E, Azais H, Uzan C, Leary A, Pautier P, Gonthier C . Surgical Outcomes After Debulking Surgery for Intraabdominal Ovarian Growing Teratoma Syndrome: Analysis of 38 Cases. Ann Surg Oncol. 2015; 22 Suppl 3:S964-70. DOI: 10.1245/s10434-015-4608-y. View

20.

Aust S, Eberst L, Tredan O, Rousset-Jablonski C, Treilleux I, Meeus P . Detailed overview on rare malignant ovarian tumors. Bull Cancer. 2020; 107(3):385-390. DOI: 10.1016/j.bulcan.2020.01.011. View